Norgalax (Docusate Sodium)

Docusate Sodium, the active ingredient in Norgalax, is a stool softener presented as a rectal formulation for rectal use. It is used to relieve occasional constipation by softening stool and facilitating easier passage. GNH USA supplies Norgalax as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norgalax is a surfactant laxative that acts on stool consistency to alleviate constipation and related conditions.

Constipation: softens stool to enable smoother bowel movements Hemorrhoids: reduces straining during defecation, helping to alleviate discomfort Pre‑operative bowel preparation: assists in clearing the lower intestine when a gentle approach is preferred

Common Side Effects: - Abdominal cramping or discomfort - Mild diarrhea or loose stools - Nausea or mild stomach upset - Rectal irritation or mild burning sensation

Serious or Rare Side Effects: - Allergic reactions such as rash, itching, or swelling - Severe abdominal pain or persistent vomiting - Rectal bleeding or severe irritation - Electrolyte imbalance in rare prolonged use

Before using Norgalax, consider the following safety measures.

Pregnancy: safety not established; use only if benefits outweigh risks Breastfeeding: unknown safety; consult a healthcare professional Kidney disease: monitor use and adjust if necessary Concurrent use with mineral oil: may reduce effectiveness of both agents Children: use with caution and under medical supervision Store at room temperature: keep in the original container, protect from moisture and heat

Norgalax may interact with other agents that affect bowel function.

Major Interactions (Avoid): - Mineral oil: can diminish the stool‑softening effect of docusate sodium - Oral antacids containing magnesium: may interfere with absorption

Moderate Interactions (Monitor Closely): - Stimulant laxatives: increased risk of abdominal cramping - Anticholinergic medications: possible reduction in bowel motility - Warfarin: rare reports of altered INR, monitor coagulation parameters